Table 1 Study characteristics
From: Effects of postnatal corticosteroids on lung development in newborn animals. A systematic review
Publication | Start of GC treatment (PND) | Duration of GC treatment (days) | Type of GC | Frequency of GC administration | Route of GC administration | Dose of GC (cumulative) | Lung injury model or co-intervention | Age at evaluation of outcome measure (PND) | Outcome measures |
|---|---|---|---|---|---|---|---|---|---|
Rat | |||||||||
Bartolome24 | 6, 10 | 1 | Dexa | Single | s.c | 10 mcg/g | None | 7, 11 | P |
Blanco25 | 4 | 10 | Dexa | Daily | s.c | 2.5 mcg | None | 14, 60 | L, LV, Morp |
Blanco26 | 18 | 10 | Dexa | Daily | s.c | 0.02 mcg/g | Hyperoxia | 28 | Ma, Morp |
Corroyer27 | 1 | 4 | Dexa | Daily tapered | s.c | 0.185 mcg/g | None | 4, 10, 16, 19, 21, 36 | P |
Dallas28 | 0, 2, 4, 6 | 1–14 | Dexa | Daily | i.p. | 3.0–6.5 mcg/g | Hyperoxia | 7, 10, 14 | I, L, Mort |
Fayon29 | 4 | 10 | Dexa HCS | Daily | s.c | Dexa: 4.4 mcg HCS: 11 mcg/g | None | 14 | L, LV, Morp, Mort |
Floros30 | 5, 14–17 | 1 | Dexa | Single, dose response | i.p. | 0.002–20 mcg/g | None | 6, 15–18 | Morp (SP-A) |
Garber31 | 1 | 14 | Dexa | Daily | s.c | 1.4 mcg | RA | 5, 10, 15, 30, 37, 52 | F, L, LV, Morp |
Gesche32 | 1, 5, 13, 19 | 2 | BMS | Daily | i.p. | 2 mcg/g | rhKGF | 3, 7, 15, 21 | L, Morp, P |
Hu33 | NR | NR | Dexa | Every other day | i.v. | NR, max 7 mcg/g | Hyperoxia | 13 | I, L, Mort |
Ishikawa34 | 0 | 14 | Dexa | Daily | i.p. | 1.3 mcg/g | Bleomycin | 14 | I, L, Morp, Mort |
Kim35 | 5 | 3 | Dexa | Daily tapered | i.p. | 0.9 mcg/g | Prenatal BMS, Hyperoxia | 8, 14 | I, L, Morp, Mort, P, V |
Le Cras36 | 3 | 11 | Dexa | Daily | s.c. | 2.75 mcg | Hypoxia | 14, 70 | L, LW, Morp, V |
Lee37 | 1 | 6 | Dexa HCS | Daily tapered | i.p. | Dexa: 1.75 mcg/g HCS: 7 mcg/g | Prenatal LPS, Hyperoxia | 7, 14 | I, L, Morp, Mort |
Lindsay38 | 0 | 1 | Dexa | Single | NR | 100 mcg/g | Hyperoxia | 2 | I |
Liu39 | 1 | 3 | Dexa | Daily | s.c. | 75 mcg | None | 3, 5, 7, 10, 14, 21 | Morp, P |
Luyet40 | 1 | 4 | Dexa | Daily tapered | s.c. | 0.185 mcg/g | None | 4, 10, 16, 19, 21, 28, 36 | P |
Massaro41 | 4 | 10 | Dexa | Daily | s.c. | 1 mcg | None | 9, 14, 20, 28, 60 | F, L, LV, Morp, P |
Massaro42 | 1 | 6 | Dexa | Daily | s.c. | 1 mcg | None | 7 | L, LW, Morp, Mort, P |
Massaro43 | 4 | 10 | Dexa | Daily | s.c. | 1 mcg | None | 6, 8, 11, 14 | L, LV, LW, Ma, Morp, P |
Massaro44 | 4 | 10 | Dexa | Daily | s.c. | 2.5 mcg | RA | 14 | L, LV, Morp |
Massaro45 | 4 | 10 | Dexa | Daily | s.c. | 2.5 mcg | RA | 37 | L, LV, Morp |
Ogasawara46 | 0, 2, 4 | 1 | Dexa | Single | i.m. | 1 mcg/g | None | 1, 3, 5 | I, L, LW, Morp |
Özer Bekmez47 | 15 | 7 | Dexa HCS MPS | Daily tapered | i.p. | Dexa: 0.725 mcg/g HCS: 18.1 mg/g MPS: 3.81 mcg/g | Hyperoxia | 22 | I, L, Morp, Mort, P |
Ross48 | 5 | 3 | Dexa | Daily | s.c. | 0.75 mcg | RA | 14 | L, Morp |
Roth-Kleiner49 | 1 | 4 | Dexa | Daily tapered | s.c. | 0.185 mcg/g | None | 4, 10, 21, 60 | Morp, V |
Roth-Kleiner50 | 1 | 4 | Dexa | Daily tapered | s.c. | 0.185 mcg/g | None | 3, 4, 6, 10, 16, 21, 36, 60 | Ma, Morp |
Sahebjami51 | 4 | 10 | Dexa | Daily | s.c. | 1 mcg | None | 99 | F, L, LV, LW, Morp, Mort, P |
Schwyter52 | 1 | 4 | Dexa | Daily tapered | s.c. | 0.185 mcg/g | None | 4, 10, 21, 36, 60 | Morp |
Shimizu53 | 0, 2, 4 | 1 | Dexa | Single | i.p. | 0.2 mcg/g | None | 1, 3, 5 | Morp |
Srinivasan54 | 3, 4 | 10 | Dexa | Daily | s.c. | 2.5 mcg | RA | 30–39 | F, L |
Theogaraj55 | 1 | 7 | Dexa | Continuously | via breastmilk | 1 mcg/ml in drinking water dams | None | 60–80 | I, L, LW, V |
Thibeault56 | 0 | 8 | Dexa | Daily tapered | s.c. | 1.8 mcg/g | Hyperoxia | 60 | F, L, LV, LW, Mort, Morp, P, V |
Tsai57 | 2 | 4 | Dexa | Daily | i.p. | 4 mcg/g | None | 7, 14, 21 | I |
Tschanz58 | 2 | 14 | Dexa | Daily | s.c. | 1.4 mcg | None | 4, 7, 10, 13, 21, 36, 44, 60 | L, LV, Morp, V |
Tschanz59 | 1 | 4 | Dexa | Daily tapered | s.c. | 0.185 mcg/g | None | 4, 10, 21, 36, 60 | L, LV, Morp, V |
Valencia60 | 5 | 3 | Dexa | Daily | i.m. | 0.3 or 1.5 mcg/g | None | 14, 21, 45 | L, LW, Ma, Mort |
Veness-Meehan61 | 3 | 10 | Dexa | Daily | NR | 2.5 mcg | Hyperoxia, RA | 14 | L, LV, Ma, Morp, Mort |
Zhang62 | 1 | 14 | Dexa | Daily | s.c. | 1.4 mcg | RA | 5, 10, 15 | Morp, P, V |
Mouse | |||||||||
Bhatt63 | 6 | 4 | Dexa | Daily | i.p. | 0.4 or 4 or 20 mcg/g | None | 10 | L, LW, V |
Clerch64 | 4 | 11 | Dexa | Daily | s.c | 5.5 or 11 mcg | RA | 15, 37 | Ma, Morp, P, V |
Hirooka65 | 3 | 10 | Dexa | Daily with 2 non-injection days | i.p. | 4 mcg | RA | 38, 90, 200 | Morp |
Kamei66 | 3 | 10 | Dexa | Daily with 2 non-injection days | s.c. | 4 mcg | None | 5, 7, 14, 21, 42 | L, LW, Ma, Morp |
Maden67 | 4 | 10 | Dexa | Daily | s.c. | 4 mcg | RA | 12 weeks | L, LV, Morp |
McGowan68 | 1 | 7, 11 | Dexa | Daily tapered | s.c. | 0.4 or 0.6 mcg/g | None | 8, 12 | Morp |
Mi69 | 7 | 7 | Dexa | Daily | i.p. | 17.5 mcg/g | Prenatal LPS | 14 | I, Morp |
Miyajima70 | 3 | 10 | Dexa | Daily with 2 non-injection days | s.c. | 4 mcg | RA | 90 | Morp |
Ohtsu71 | 14 | 4 | Dexa | Daily | s.c. | 0.4 or 4 or 20 mcg/g | Hyperoxia | 18 | F, Morp, Mort |
Stinchcombe72 | 4 | 10 | Dexa | Daily with 2 non-injection days | s.c. | 4 mcg | RA, 2 different mouse strains | 90 | L, LV, Morp |
Zhuang73 | 3 | 7, 11 | Dexa | Daily | s.c. | 7 or 11 or 2.75 mcg | HO-1 knockout | 10, 14 | Morp, V |
Guinea pig | |||||||||
Town74 | 0 | 3 | Dexa | Daily | s.c. | 30 mcg/g | Prematurity, Hyperoxia | 3, 5, 7 | I, L, LW, Mort |
